Hydrophilic iminosugar active‐site‐specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients
Authors:
Open Access
- 17 August 2006
- journal article
- Published by Wiley in The FEBS Journal
- Vol. 273 (17) , 4082-4092
Abstract
Gaucher disease is an autosomal recessive lysosomal storage disorder caused by the deficient activity of glucocerebrosidase. Accumulation of glucosylceramide, primarily in the lysosomes of cells of the reticuloendothelial system, leads to hepatosplenomegaly, anemia and skeletal lesions in type I disease, and neurologic manifestations in types II and III disease. We report herein the identification of hydrophilic active‐site‐specific chaperones that are capable of increasing glucocerebrosidase activity in the cultured fibroblasts of Gaucher patients. Screening of a variety of natural and synthetic alkaloid compounds showed isofagomine, N‐dodecyl deoxynojirimycin, calystegines A3, B1, B2 and C1, and 1,5‐dideoxy‐1,5‐iminoxylitol to be potent inhibitors of glucocerebrosidase. Among them, isofagomine was the most potent inhibitor of glucocerebrosidase in vitro, and the most effective active‐site‐specific chaperone capable of increasing residual glucocerebrosidase activity in fibroblasts established from Gaucher patients with the most prevalent Gaucher disease‐causing mutation (N370S). Intracellular enzyme activity increased approximately two‐fold after cells had been incubated with isofagomine, and the increase in glucocerebrosidase activity was both dose‐dependent and time‐dependent. Western blotting demonstrated that there was a substantial increase in glucocerebrosidase protein in cells after isofagomine treatment. Immunocytochemistry revealed an improvement in the glucocerebrosidase trafficking pattern, which overlaps that of lysosome‐associated membrane protein 2 in Gaucher fibroblasts cultivated with isofagomine, suggesting that the transport of mutant glucocerebrosidase is at least partially improved in the presence of isofagomine. The hydrophilic active‐site‐specific chaperones are less toxic to cultured cells. These results indicate that these hydrophilic small molecules are suitable candidates for further drug development for the treatment of Gaucher disease.Keywords
This publication has 33 references indexed in Scilit:
- Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's diseaseThe International Journal of Biochemistry & Cell Biology, 2005
- ERAD: the long road to destructionNature Cell Biology, 2005
- Therapeutic approaches to protein-misfolding diseasesNature, 2003
- The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statementJournal of Inherited Metabolic Disease, 2003
- A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activityTrends in Pharmacological Sciences, 2003
- X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher diseaseEMBO Reports, 2003
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999
- Folding of Secretory and Membrane ProteinsNew England Journal of Medicine, 1998
- Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's diseaseBiochemical and Biophysical Research Communications, 1965